450 Simeprevir/Sofosbuvir Therapy in Hepatitis C (HCV) Infected Patients With Child-Pugh Class B/C Cirrhosis Compared to Matched Untreated and Protease Inhibitor (PI)-Triple Therapy Treated Control
All-oral therapy offers safety advantages for patients with decompensated cirrhosis. The risks/benefits of simeprevir (SIM) plus sofosbuvir (SOF) in patients with Child-Pugh (CP) B/C cirrhosis are unknown. We aim to assess safety and sustained virologic responses (SVR) of SIM+SOF±ribavirin (RBV) in CP-B/C cirrhosis and to compare results to matched untreated and PI (telaprevir or boceprevir)-triple therapy treated controls. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - April 28, 2015 Category: Gastroenterology Authors: Varun Saxena, Lisa M. Nyberg, Mary Patricia Pauly, Joanna Ready, Jean-Luc Szpakowski, Barbara Piasecki, Anders H. Nyberg, Bradley J. Winston, Jacquelyn L. Redd, Lisa Catalli, Aditi Dasgupta, Stephanie Straley, Kali Sommer, Gayle Witt, Robert Rathbun, Nora Tags: Oral abstract Source Type: research
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
CONCLUSION: Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level.
PMID: 25914481 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 21, 2015 Category: Gastroenterology Authors: Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J Tags: World J Gastroenterol Source Type: research
Management of hepatitis C infection before and after liver transplantation.
Abstract
Chronic hepatitis C (CHC) is the most common indication for liver transplantation (LT). Aggressive treatment of hepatitis C virus (HCV) infection before cirrhosis development or decompensation may reduce LT need and risk of HCV recurrence post-LT. Factors associated with increased HCV risk or severity of recurrence include older age, immunosuppression, HCV genotype 1 and high viral load at LT. HCV recurrence post-LT leads to accelerated liver disease and cirrhosis development with reduced graft and patient survival. Currently, interferon (IFN)-based regimens can be used in dual-agent regimens with...
Source: World Journal of Gastroenterology : WJG - April 21, 2015 Category: Gastroenterology Authors: Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L Tags: World J Gastroenterol Source Type: research
Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases
Conclusions Baseline anti-E1E2 could be considered as a new biomarker to predict SVR12 after triple therapy in this most difficult-to-treat population. These results warrant further validation on larger cohorts including patients receiving highly effective direct-acting antivirals to explore whether this test could help in better defining treatment duration for these very costly molecules. (Source: Clinics and Research in Hepatology and Gastroenterology)
Source: Clinics and Research in Hepatology and Gastroenterology - April 18, 2015 Category: Gastroenterology Source Type: research
Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy
No abstract available (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - April 14, 2015 Category: Infectious Diseases Tags: Letters to the Editor Source Type: research
